Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-62296
Soyka, Jan D; Muster, Marco A; Schmid, Daniel T; Seifert, Burkhardt; Schick, Ulrike; Miralbell, Raymond; Jorcano, Sandra; Zaugg, Kathrin; Seifert, Hans-Helge; Veit-Haibach, Patrick; Strobel, Klaus; Schaefer, Niklaus G; Husarik, Daniela B; Hany, Thomas F (2012). Clinical impact of (18)F-choline PET/CT in patients with recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 39(6):936-943.
PDF - Registered users only
PURPOSE: To investigate the clinical value of (18)F-fluorocholine PET/CT (CH-PET/CT) in treatment decisions in patients with recurrent prostate cancer (rPCA).
METHODS: The study was a retrospective evaluation of 156 patients with rPCA and CH-PET/CT for restaging. Questionnaires for each examination were sent to the referring physicians 14-64 months after examination. Questions included information regarding initial extent of disease, curative first-line treatment, and the treatment plan before and after CH-PET/CT. Additionally, PSA values at diagnosis, after initial treatment, before CH-PET/CT and at the end of follow-up were also obtained from the questionnaires.
RESULTS: Mean follow-up was 42 months. The mean Gleason score was 6.9 at initial diagnosis. Initial treatment was: radical prostatectomy in 110 patients, radiotherapy in 39, and combined prostatectomy and radiotherapy in 7. Median PSA values before CH-PET/CT and at the end of follow-up were 3.40 ng/ml and 0.91 ng/ml. PSA levels remained stable, decreased or were below measurable levels in 108 patients. PSA levels increased in 48 patients. In 75 of the 156 patients (48%) the treatment plan was changed due to the CH-PET/CT findings. In 33 patients the therapeutic plan was changed from palliative treatment to treatment with curative intent. In 15 patients treatment was changed from curative to palliative. In 8 patients treatment was changed from curative to another strategy and in 2 patients from one palliative strategy to another. In 17 patients the treatment plan was adapted.
CONCLUSION: CH-PET/CT has an important impact on the therapeutic strategy in patients with rPCA and can help to determine an appropriate treatment.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology|
04 Faculty of Medicine > Institute of Social and Preventive Medicine
|DDC:||610 Medicine & health|
|Deposited On:||21 May 2012 13:51|
|Last Modified:||05 Mar 2014 18:47|
|Additional Information:||The final publication is available at www.springerlink.com|
|Citations:||Web of Science®. Times Cited: 14|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page